Siligmueller & Norvid Wealth Advisors’s AbbVie ABBV Stock Holding History

Siligmueller & Norvid Wealth Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$2.88M	Buy	+12,436	New	+$2.53M	1.29%	25

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Siligmueller & Norvid Wealth Advisors's ABBV Position: Q3 2025 in Review

Siligmueller & Norvid Wealth Advisors opened a new position in AbbVie (ABBV) in Q3 2025: 12,436 shares worth $2.88M. The stake represents 1.29% of the portfolio and ranks #25 among its holdings.

3,909 funds tracked by Wall St. Rank hold ABBV as of Q3 2025.

Siligmueller & Norvid Wealth Advisors held 12,436 shares of AbbVie worth $2.88M as of Q3 2025.
AbbVie was a new Siligmueller & Norvid Wealth Advisors position in Q3 2025.
AbbVie made up 1.29% of Siligmueller & Norvid Wealth Advisors's portfolio in Q3 2025, its #25 holding.
3,909 funds tracked by Wall St. Rank held AbbVie as of Q3 2025.

Based on Siligmueller & Norvid Wealth Advisors's 13F filing for Q3 2025, filed 10 Nov 2025.